Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;13(4):450-455.
doi: 10.6004/jadpro.2022.13.4.7. Epub 2022 Jun 21.

Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma

Jessica Davis  1 , Megan Wayman  2
Affiliations

Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma

Jessica Davis et al. J Adv Pract Oncol. 2022 May.

Abstract

The treatment landscape for metastatic melanoma has changed dramatically over the past few years as new medications have been developed. Encorafenib, a B-Raf protein kinase inhibitor, and binimetinib, a MEK inhibitor, were approved by the U.S. Food and Drug Administration in 2018 for the treatment of patients with unresectable or metastatic melanoma which harbor a BRAF V600E or V600K mutation. These approvals were based on findings from the COLUMBUS trial, which demonstrated improvement in progression-free survival and overall survival with the combination of encorafenib plus binimetinib compared with vemurafenib alone. Encorafenib plus binimetinib is the third BRAF plus MEK inhibitor combination to be approved, and there are clinical and practical differences between the combination regimens that should be considered when selecting an appropriate treatment regimen for patients.

PubMed Disclaimer

Conflict of interest statement

Dr. Davis has served on advisory boards for Array BioPharma, Exelixis, Inc., and Sanofi-Genzyme/Regeneron Pharmaceuticals, and on a speakers bureau for Exelixis, Inc. Dr. Wayman has no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
MAPK pathway and targets of BRAF/MEK inhibitors. Adapted from Sood et al. (2021).
See this image and copyright information in PMC

References

    1. Array Biopharma Inc. (2018a). Braftovi (encorafenib) package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf
    1. Array Biopharma Inc. (2018b). Mektovi (binimetinib) package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf
    1. Ascierto, P. A., Breno, B., Larkin, J., Ribas, A., Liszkay, G., Maio, M., & McArthur, G.A. (2021). 5-year outcomes with cobimetinib plus vemurafenib in BRAF V600 mutation-positive advanced melanoma: Extended follow-up of the coBRIM study. Clinical Cancer Research, 27(19), 5225–5235. 10.1158/1078-0432.CCR-21-0809 - DOI - PMC - PubMed
    1. Cheng, L., Lopez-Beltran, A., Massari, F., MacLennan, G. T., & Montironi, R. (2018). Molecular testing for BRAF mutations to inform melanoma treatment decisions: A move toward precision medicine. Modern Pathology, 31(1), 24–38. 10.1038/modpathol.2017.104 - DOI - PMC - PubMed
    1. Delord, J. P., Robert, C., Nyakas, M., McArthur, G. A., Kudchakar, R., Mahipal, A., & Dummer, R. (2017). Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clinical Cancer Research, 23(18), 5339–5348. 10.1158/1078-0432.CCR-16-2923 - DOI - PubMed

LinkOut - more resources